Medical Director, Recognition and Prevention Program (RAP) The Zucker Hillside Hospital
Professor, Psychiatry and Molecular Medicine, Hofstra North Shore-LIJ School of Medicine
Investigator, The Feinstein Institute for Medical Research
Phone: (718) 470-4812
Dr. Christoph U. Correll is a professor of psychiatry and molecular medicine at Hofstra North Shore-LIJ School of Medicine in New York. He is further the medical director of the Recognition and Prevention (RAP) Program at the Zucker Hillside Hospital, Queens, New York, and director of the Adverse Events Unit and the Core Laboratory Unit, each at the Zucker Hillside Hospital Advanced Center for Intervention and Services Research.
Dr. Correll completed his medical studies at both the Free University of Berlin, Germany, and Dundee University Medical School in Scotland. After finishing his general psychiatry residency, he also trained in child and adolescent psychiatry, both at The Zucker Hillside Hospital in Queens, New York.
Dr. Correll’s research and clinical work focus on the identification and treatment of patients with severe psychiatric disorders. His areas of expertise include schizophrenia-spectrum, mood-spectrum and aggressive-spectrum disorders, ranging from the prodrome to first episode, multi-episode and refractory illness patients. He is further an expert in the risk-benefit evaluation of psychotropic medications, including the interface between psychiatry and medicine and the assessment of comparative effectiveness, both in prospective studies and meta-analytic evaluations.
Dr. Correll has authored over 200 journal articles. He has served on a number of expert consensus panels, is a reviewer for over 70 peer-reviewed journals and an editorial board member of ten scientific journals. Dr. Correll is the principal investigator or Steering Committee member of several large, federally funded grants and has received over two dozen national and international research awards and fellowships for his work.
Dr. Correll’s research and clinical work focus on the identification, characterization and psychopharmacological management of adults and youth with severe psychiatric disorders. His areas of expertise include schizophrenia, bipolar disorder, major depression and other psychotic, mood and autism/disruptive behavior spectrum disorders, ranging from the prodrome to first episode, multi-episode and refractory illness patients. His work focuses further on the risk-benefit evaluation of psychotropic medications, including the interface between psychiatry and medicine and investigations of the extent and mechanisms of neuromotor and cardiometabolic adverse effects.
Dr. Correll and his team are conducting several studies on beneficial effects and side effects of antipsychotics and mood stabilizers; symptomatic, diagnostic and functional outcomes of youth with psychiatric problems and on clinical and biological risk factors and protective factors predicting outcomes. These research projects involve naturalistic and randomized treatment, controlled and observational studies.
SATIETY study (sponsor: National Institute of Mental Health): children and adolescents (age 4-19 years) who start clinically decided antipsychotic treatment are followed in an observational cohort study design to assess the risks and benefits of these medications under real world conditions. Effectiveness, adverse effects and clinical and biological predictors of these effects are studied.
IMPACT study (sponsor: National Institute of Mental Health): children and adolescents (age 8-19 years) who have gained significant amount of their body weight over the past 3 years on an antipsychotic and who are overweight are randomized to up to 6 months of open treatment of a) healthy lifestyle instruction alone or b) addition of metformin or c) a switch to a lower risk antipsychotic.
STRATEGY study: children and adolescents (age 10-19 years) who are either starting antipsychotic treatment for the first time ever, or who have gained at least 10% of their body weight over the past 12 months while treated with an antipsychotic are randomized to 3 months of open treatment of a) healthy lifestyle instruction alone or b) addition of metformin.
Adolescent Mood Disorder and Psychosis Study: children and adolescents (age 12-18 years) who have a clinical diagnosis of a mood or psychosis spectrum disorder are interviewed to comprehensively characterize their psychiatric problems and followed in an observational cohort design to assess symptomatic and functional outcomes over time.
Dr. Correll has authored or co-authored over 200 journal articles. He has served on several expert consensus panels on the use of antipsychotics across a range of psychiatric disorders, is a reviewer for over 70 peer-reviewed journals and an editorial board member of ten scientific journals. Dr. Correll is the principal investigator or Steering Committee member of several large, federally funded grants and has received over two dozen national and international research awards and fellowships for his work.
Free University of Berlin, Berlin, Germany
Field of Study: Pre-Medicine & Medicine
Dundee University, Dundee, Great Britain
Field of Study: Medicine
Neurologische Klinik GmbH, Bad Neustadt, Germany
Field of Study: Neurology Residency
PGY-1, Beth Israel Medical Center, New York, NY
Field of Study: Psychiatry Residency
Hillside Hospital, Glen Oaks, NY
Field of Study: Psychiatry Research Residency (Chief)
Schneider Children’s Hospital, New Hyde Park, NY
Field of Study: Child & Adolescent Psychiatry Fellow
2002 11th Biennial Winter Workshop on Schizophrenia Young Scientist Award; Peter Henderson, M.D., Memorial Paper Award; Clinical Research Methodology Workshop American Society of Clinical Psychopharmacology Fellowship Award; APA/Lilly Resident Research Award; Seventh APA Research Colloquium for Junior Investigators Award; ACAP Presidential Scholar Award
2003 AADPRT George Ginsberg Fellowship Award; American Federation for Medical Research Clinical Research 2003 Conference Travel Award; American Federation for Medical Research Henry Christian Award; APA Research Colloquium for Junior Investigators Award; Clinical Research Methodology Workshop American Society of Clinical Psychopharmacology Fellowship Award; John and Maxine Bendheim Fellowship Award for Research
2004 APA Research Colloquium for Junior Investigators Award; AACAP Pilot Research Award; North Shore – Long Island Jewish Research Institute Faculty Research Award
2005 International Congress on Schizophrenia Research Young Investigator Award; First NIMH-sponsored Career Development Institute for BPD Fellowship Award; First Neuroleptic Malignant Syndrome Information Service 2004-2005 Promising New Investigators Award
2007 NARSAD Young Investigator Award
2013 John and Maxine Bendheim Fellowship Award for Research
- De Hert M, Correll CU, Cohen D. “Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study.” Schizophr Res. 2010 Mar;117(1):68-74.
- Correll CU, Sheridan EM, DelBello MP. “Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials.” Bipolar Disord. 2010;12(2):116-141.
- Correll CU. “Switching and combining antipsychotics.” CNS Spectr. 2010 Apr;15(4 Suppl 6):8-11.
- Correll CU*, Hauser M*, Auther AM, Cornblatt BA. “Research in people with psychosis risk syndrome: a review of the current evidence and future directions.” J Child Psychol Psychiatry. 2010 Apr;51(4):390-431.
- Maayan L, Vakhrusheva J, Correll CU. “Effectiveness of Medications Used to Reduce Antipsychotic-Related Weight Gain and Metabolic Abnormalities: A Systematic Review and Meta-analysis.” Neuropsychopharmacology. 2010 Jun;35(7):1520-30.
- Correll CU. “From receptor pharmacology to improved outcomes: individualizing the selection, dosing, and switching of antipsychotics.” Eur Psychiatry. 2010 Jun;25 Suppl 2:S12-21.
- Heald A, Montejo AL , Millar H, De Hert M, McCrae J, Correll CU. “Management of physical health in patients with schizophrenia: practical recommendations.” Eur Psychiatry. 2010 Jun;25 Suppl 2:S41-5.
- Kane JM, Barnes TR, Correll CU, Sachs G, Buckley P, Eudicone J, McQuade R, Van Tran Q, Pikalov A 3rd, Assunção-Talbott S. “Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.” J Psychopharmacol. 2010 Jul;24(7):1019-29.
- Maayan L, Correll CU. “Management of antipsychotic-related weight gain.” Expert Rev Neurother. 2010 Jul;10(7):1175-200.
- Nielsen J, Skadhede S, Correll CU. “Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia Patients.” Neuropsychopharmacology. 2010 Aug;35(9):1997-2004.